PSA Response to Tri-modality (HDR Brachytherapy, Hypofractionated 3D-CRT, Neoadjuvant/Adjuvant Androgen Therapy) Predicts Biochemical Progression-free Survival in Localized Prostate Cancer

Abstract

High dose rate (HDR) brachytherapy combined with external beam radiation therapy (EBRT), neoadjuvant androgen suppression therapy (NAST) and adjuvant androgen suppression therapy (AAST) (Tri-modality) have been used to treat localized high risk prostate cancer. To define prognostic factors of biochemical relapse free survival (bRFS), an analysis of patients treated with Tri-modality were performed.